News
-
Prevention strategies for all: Launch of the 2025 Canadian HIV PEP & PrEP Guideline
Led by Dr. Darrell Tan and supported by the CTN+, this document provides the most update-to-date evidence for…
-
How small changes are making big strides in prison harm reduction
One in four people in Canadian federal prisons have been previously exposed to hepatitis C. Hepatitis C can…
-
Welcoming the 2025 Cohort of CTN+ Postdoctoral Fellows
The CTN+ is dedicated to supporting HIV and STBBI research across Canada, and a crucial part of that…
-
Postdoc Spotlight: Hajar Miranzadeh
Hajar Miranzadeh moved to Canada in 2015 to start her PhD in Pharmacology at the University of Saskatchewan.…
-
-
Postdoc Spotlight: Dr. Katherine Kooij
Dr. Katherine Kooij, a medical doctor and epidemiologist, started her CTN fellowship in 2022. Her interest in HIV…
-
Postdoc Spotlight: Dr. Alice Zhabokritsky
Dr. Alice Zhabokritsky embarked on her CTN fellowship in the summer of 2021 upon completion of her infectious…
-
Putting data into action: How CTN researchers track, prevent, and manage HIV in infants
The Canadian Pediatric and Perinatal HIV/AIDS Research Group is a collection of clinicians and researchers that form the…
-
Guest blog: Dr. Oscar Javier Pico Espinosa
CTN Postdoctoral Fellow Dr. Oscar Javier Pico Espinosa shares his journey to becoming a researcher in the HIV…
Resources
Our Resource Library is a place to share documents, videos, and training resources about HIV and STBBI research and related topics.
There are no results message
Studies
The CTN+ supports clinical trials, implementation science projects, and non-interventional research of the highest scientific and ethical standards.
-
CTNPT 055: Testing Immunogenicity and Durability of Mpox Vaccination in People Living with HIV
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
-
CTN 343: Project ReportNeedles.ca
Project ReportNeedles.ca: A rapid assessment and response system to map needle prevalence and implement harm reduction interventions in Regina, Saskatchewan
-
CTN 260: Raltegravir switch study
A randomized prospective open-label study of switching to raltegravir based antiretroviral therapy (ART) compared to maintaining ritonavir boosted protease inhibitor-based ART on liver fibrosis progression in HIV-HCV co-infected individuals
Publications
Our researchers and trainees have produced hundreds of peer-reviewed publications in a wide range of HIV- and STBBI-related areas.